PAVmed Q3 net loss $6.3M; Veris relaunches implant monitor; Lucid gets Medicare support

PAVmed Inc.

2025-Q3 EPS reported -$0.11 revenue$19,000

GAAP net loss $6.3M ($0.29 diluted EPS); non-GAAP adj loss $0.4M ($0.02) for Q3 2025.
Lucid Diagnostics: $1.2M EsoGuard revenue, 2,841 tests processed; CAC unanimously supported Medicare coverage.
Veris Health launched commercial phase of OSU partnership, relaunched implantable monitor for planned 2026 FDA submission.
PAVmed signed LOI with Duke University to license endoscopic esophageal imaging technology via new subsidiary.
PAVmed cash $3.1M (Sep 30) vs $1.2M (Dec 31, 2024); Lucid netted ~$27M from public offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.